Introduction {#Sec1}
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Aging is a multi-factorial process that adversely affects the fitness of adult organisms over time, ultimately leading to death. Although the mechanisms underlying age-related degeneration and death in various species need to be identified, an evolutionally conserved pathway has begun to emerge ([@CR48]). Ample recent evidence, mostly obtained from short-lived invertebrate organisms (e.g., *Drosophila melanogaster* and *Caenorhabditis elegans*), supports the evolutionary theory of aging, which subsequently has become an important basis for addressing the question of how we age ([@CR40]). Studies in model organisms have begun to map out important genes and pathways that seem to regulate the pace of aging and are remarkably conserved from yeast to mice ([@CR70]). Interestingly, most of these 'longevity genes' are found to be involved in the control of identifiable signaling pathways that can be activated by environmental stimuli and influence life history traits related to stress resistance, diapause, reproduction and life expectancy ([@CR70]). Perturbation of neuroendocrine signals, especially insulin-like growth factor-1 (IGF-1), is closely associated with changes in animal lifespan and age-dependent function ([@CR70]).

In invertebrates, reduced insulin/IGF signaling pathway significantly increased adult lifespan ([@CR70]; [@CR40]). In mice, mutations of transcription factors *Prop1* and *Pit 1* impede pituitary production of growth hormone, thyroid-stimulating hormone and prolactin; reduce growth rate and adult body size; and increase adult lifespan by 40% to 60% ([@CR6]; [@CR33]). Mice with mutation of growth hormone receptor (GHRKO) have similar extension of lifespan ([@CR79]). Expressed throughout life, these mutations produce many secondary alterations in endocrine systems, including profound suppression of circulating IGF-1. Furthermore, mice heterozygous for the disruption of IGF-1 receptor IGF1r (IGF1r+/j) also live longer than wild-type controls ([@CR41]). Interestingly, caloric restriction is well documented to delay aging and prolong life in laboratory animals. In caloric-restricted animals, plasma IGF-1 levels were reduced ([@CR6]).

Besides the essential role of regulating somatic growth and development, insulin-like growth factor-1 is also important in neuronal function. During development of the nervous system, IGF-1 plays a prominent neurotrophic role, stimulating differentiation and survival of specific neuronal populations ([@CR75]; [@CR74]). In the adult central nervous system (CNS), IGF-1 is a neuromodulator and is involved in regulation of synaptic plasticity ([@CR71]). IGF-1 levels are reduced with age. Restoring IGF-1 levels was reported to enhance neurogenesis and ameliorate the age-related cognitive malfunction in aged brain ([@CR54]). Furthermore, in transgenic mice with increased expression of IGF-1 in the brain, the weight and volume of the brain are increased substantially due to increases in neuron number and total myelin ([@CR29]), whereas transgenic mice with ectopic brain expression of IGFBP-1, an inhibitor of IGF action, and mice with ablated IGF-1 gene expression have brain growth retardation with impaired neuronal somatic and dendritic growth ([@CR29]; [@CR23]). Further, IGF-1 gene deletion in humans is associated with mental retardation ([@CR76]).

The Ames dwarf mouse is a murine model of circulating GH and IGF-1 deficiency that exhibits dwarf phenotype characteristics and significantly extended lifespan, the result of a homozygous mutation at the *Prop-1* locus on chromosome 11 ([@CR7]; [@CR14]). Surprisingly, in addition to extended lifespan and delayed physical aging, Ames dwarf mice do not experience an age-related decline in cognitive function when compared with their young counterparts, as measured in behavioral tests ([@CR47]). The results of our recent work show that genetically GH deficient Ames dwarf mice have elevated levels of IGF-1 in the hippocampus, while the level of the corresponding mRNA is as high as in normal mice ([@CR68], [@CR69]).

Aging and hippocampal neurogenesis {#Sec2}
==================================

Cognitive functions show many alternative outcomes during aging ([@CR48]). Individual trajectories range from the devastating effects of Alzheimer's disease (AD) and multiinfarct dementia (MID) to very mild changes detected during middle-age that may become more pronounced in later life without interfering with most daily activities. The hippocampal formation, a temporal lobe brain structure involved in various types of learning and memory, has been implicated in age-related memory dysfunction. Its functional integrity is critical for normal memory function, and it is very vulnerable to the process of aging ([@CR43]; [@CR31]). The ability to learn new tasks decreases with age, particularly in spatial memory ([@CR31]). At the cellular level, synaptic contacts, synaptic strength and plasticity are reduced during aging ([@CR5]). Furthermore, the cognitive impairment is associated with deterioration of hippocampal circuitry and plasticity ([@CR65]), suggesting that the age-associated spatial learning impairment might be explained by deficiencies in hippocampal spatial information processing.

Studies of the hippocampus reveal a number of types of structural plasticity, including neurogenesis in the dentate gyrus, remodeling of dendrites and the formation and replacement of synapses. These changes, along with compensatory neurochemical and neuroendocrine responses, provide the brain with a considerable amount of resilience. Within the hippocampus there are several cellular types, including large principal pyramidal and nonprincipal cells of the CA regions ([@CR34]) and small granule neurons of the dentate gyrus (DG). One of the most exciting neuroscience discoveries of the past decade is the birth of new neurons that occur in discrete regions of the adult mammalian brain, namely the subgranular zone (SGZ) of the hippocampal dentate gyrus and in the subventricular zone (SVZ) ([@CR1], [@CR2]; [@CR34]). In these regions, regulation of adult neurogenesis is often demonstrated by systemic injection of an exogenous synthetic S-phase marker such as bromo-deoxyuridine (BrdU), the thymidine analogue, which is taken up by dividing cells during the S-phase ([@CR57]). This technique has shown that neural progenitor cells arising from the subgranular zone migrate into the granule cell layer (GCL) where they differentiate into new neurons and integrate into the local network, receiving afferents and sending out functional efferents ([@CR16]), whereas SVZborn neurons are destined for the olfactory bulb (OB) ([@CR62]). The process of neurogenesis in the adult dentate gyrus can be divided into three distinct phases. First, neural precursor cells that reside at the border between the hilus and the granule cell layer undergo cell division. Second, newborn cells begin to migrate into the GCL and extend neuronal processes. Third, the cells integrate into the GCL and begin to express the neuronal marker. These newly born neurons have electrophysiological properties of mature neurons, conduct action potentials, and make functional synapses with the adult granule cell ([@CR73]). It has also been suggested that newly generated neurons in adulthood may have an important physiological role, because blockade of hippocampal neurogenesis is reported to inhibit hippocampus-dependent learning ([@CR64]), and because reducing the population of new interneurons in the OB impairs odor discrimination ([@CR36]).

Neurogenesis in the dentate gyrus occurs throughout the lifespan, but decreases with age in rats, mice, monkeys and humans ([@CR80]; [@CR15]; [@CR39]). Several studies have suggested that cognitive decline in aging may be attributable to decreased dentate gyrus neurogenesis ([@CR64]; [@CR30]). Conversely, hippocampal neurogenesis was reported to increase in aged mice living in an enriched environment ([@CR45]). Enhanced neurogenesis is accompanied by improved learning, exploratory behavior and locomotor activity ([@CR45]). Therefore, it is suggested that restoring hippocampal neurogenesis may be a strategy for reversing age-related cerebral dysfunction. In addition, growth factors stimulate proliferation of neuronal precursors in the adult brain in vitro and in vivo. For example, fibroblast growth factor (FGF)-2 is expressed in adult rodent SVZ and SGZ ([@CR38]), and intracerebroventricular (ICV) infusions of FGF-2 upregulate dentate neurogenesis considerably in the aged brain and also increase neurogenesis in SVZ and neuronal migration to OB ([@CR50]; [@CR44]).

Insulin-like growth factor-1 is another interesting component that stimulates neurogenesis, via a pattern of regulation across lifespan ([@CR3]). IGF-1 is a 7.5 kDa protein, and yet it can be taken up into CSF by a process that is independent of IGF receptors or binding proteins ([@CR59]). In rodents, voluntary exercise in a running wheel has been reported to increase neurogenesis in the dentate gyrus ([@CR73]). Such exercise increases the uptake of IGF-1 from the blood and activates c-fos protein expression in dentate gyrus and other brain regions in a manner that is mimicked by IGF-1 administration into the circulation ([@CR19]). Moreover, immunoneutralization of IGF-1 blocks the effects of exercise to enhance neurogenesis ([@CR72]). Blockade of IGF-1 has also been shown to prevent exercise-induced neurogenesis, demonstrating IGF-1 as a necessary component of physical activity-induced neurogenesis ([@CR72]).

IGF-1 expression and actions in the central nervous system {#Sec3}
==========================================================

In the murine brain IGF-1 expression begins at approximately embryonic day 14, peaks in the second postnatal week, and then declines but continues throughout life ([@CR28]). IGF-1 mRNA expression is predominately located in neurons and astrocytes and, to a lesser extent, in oligodendrocytes and their precursors ([@CR63]). Because IGF-1 mRNA is detected in the subventricular zone during early development ([@CR10]), IGF-1 may also be expressed by neural stem cells and early glial progenitors. As CNS development progresses, regional IGF-1 expression often peaks concurrently with the proliferation of neural cells. In addition, this expression occurs immediately prior to the peak time of myelinspecific protein gene expression and rapid myelination ([@CR67]; [@CR17]). The type-1 IGF receptor, which is the predominant, if not exclusive, mediator of IGF-1 actions, is expressed by neuronal stem cells ([@CR13]) and subsequently appears to be expressed in all neural cells. These studies strongly indicate that IGF-1 plays an important role in CNS development by acting in an autocrine and/or paracrine fashion. In addition, a variety of insults that result in CNS demyelination induce IGF-1 gene expression near or at the sites of injury ([@CR35]; [@CR77]), suggesting a role for IGF-1 in protecting oligodendrocytes from injury and/or in promoting their regeneration following injury.

The brain requires enormous supplies of fuel to support neuroglial growth and process formation during early postnatal development. Murine and human brains consume over half the energy available to the organism as a whole during this critical period ([@CR37]), while undernutrition may result in permanent intellectual deficit ([@CR21]). How the developing brain competes so successfully with peripheral tissues for resources is unknown. Insulin preferentially enhances fuel and substrate utilization by peripheral tissues but does not seem to be involved in the regulation of brain metabolism ([@CR11]). Very little insulin is synthesized within the brain ([@CR11]) and little circulating insulin can cross the blood-brain barrier ([@CR60]). However, IGF-1 is abundant in the developing brain, where it is concentrated in large projection neurons ([@CR12]). IGF-1 and insulin receptors are also homologous, with nearly identical signaltransducing domains engaging many of the same intracellular pathways. Recent studies suggest that endogenous brain IGF-1 may play an essential, insulin-like role in brain glucose metabolism ([@CR22]).

In vitro studies have shown that IGF-1 stimulates the proliferation of neuron progenitors, induces the differentiation of oligodendrocytes, and increases the survival of neurons and oligodendrocytes (see review in [@CR29]). IGF-1 effects on CNS suggested by in vitro studies have been confirmed in vivo. Multiple lines of mice with genomic alterations in their IGF systems have been generated. IGF-1 overexpressing mice were among the first transgenic mice generated ([@CR56]). Depending upon the tissues and magnitude of transgene expression among the transgenic mice, postnatal somatic overgrowth begins at 3--4 weeks of age and leads to a moderate increase in weight by early adulthood. The IGF-1 transgenic mice exhibit disproportional overgrowth of some organs, most remarkably of the brain ([@CR29]). Interestingly, transgenic mice with larger brain weights usually do not exhibit somatic overgrowth; rather they have modestly reduced adult body weight and similarly reduced serum IGF-1 levels ([@CR78]).

Recently, by the use of a variety of promoters aimed at generating organ- or tissue-specific IGF-1 overexpression, a number of other IGF-1 transgenic mice have been created ([@CR29]). At the same time, generation and study of mice with IGF-1 and the IGF-1 receptor null mutation are providing direct evidence of the central role of IGF-1 in somatic growth ([@CR32]). Mice with disrupted IGF-1 and IGF-R gene exhibit marked in utero and postnatal growth retardation and have reduced survival past birth ([@CR52]; [@CR4]; [@CR58]). The brains of IGF-1 knockout (KO) and IGF-1R KO mice are smaller than those of controls, although the brains are not as growth-retarded as the body weights, and the brain phenotype in each appears to be similar. IGFBP-1 is an inhibitor of IGF action and would be expected to inhibit the actions of endogenous IGF-1 and IGF-1I. Using different promoters, several groups have created IGFBP-1 transgenic mice. These transgenic mice exhibit somatic and brain growth retardation ([@CR27]; [@CR26]). Collectively, these studies provided compelling evidence that IGF-1 promotes growth of the brain by increasing neuron number, process outgrowth and synaptogenesis. IGF-1 acts to increase neuron number by increasing the rate of neuron proliferation while inhibiting apoptosis in place of naturally occurring neuron death, suggesting its neuronal protective action. Some regions of the brain, notably the hippocampus dentate gyrus, appear to have a greater dependency on the growth-promoting effect of IGF-1.

Levels of IGF-1 and the type-1 IGF receptor decrease in several regions of the brain during normal aging ([@CR66]), and administration of IGF-1 can counteract some age-related changes in brain energy metabolism and function ([@CR53]). Recent evidence that IGF-1 signaling is involved in the development of Alzheimer's diseases (ADs) are gaining attention ([@CR18]; [@CR20]). High brain amyloid-beta levels are found at an early age in mutant mice with low circulating IGF-1, and amyloid-beta burden can be reduced in aging rats by increasing serum IGF-1 ([@CR18]). Tau phosphorylation, which causes the formation of neurofibrillary tangles and senile plaques in AD, was dramatically increased in the brain of IGF1 −/− mice ([@CR24]). This evidence suggests that IGF-1 can protect neurons against insults relevant to the pathogenesis of Alzheimer's disease, stroke and other age-related neurological disorders and can enhance learning and memory.

Adult neurogenesis in the long-lived mutant mice {#Sec4}
================================================

Ames dwarf mice {#Sec5}
---------------

The first mammalian mutant found to have an increased average and maximal lifespan was the Ames dwarf mouse ([@CR8], [@CR9]; [@CR14]). Depending on gender and genetic background, extensions of about 50% in average lifespan and 40% in maximal lifespan are observed ([@CR14]). The Ames dwarf mouse is of considerable significance: clinical evidence suggests that humans with mutated Prop1 may show increased longevity ([@CR49]; [@CR61]). Ames dwarf mice display phenotypes of dwarfism (they are about one-third normal size), reduced growth rate, and deficiencies in circulating GH, prolactin, thyroid-stimulating hormone (TSH) and IGF-1 ([@CR8], [@CR9]; [@CR14]). Males exhibit variable fertility, but females are infertile as a result of a lack of prolactin (treatment with prolactin restores fertility) ([@CR9]). Both genders display delayed reproductive maturity ([@CR8]; [@CR14]). A number of aging-related phenotypes are also delayed, including fatal neoplastic disease and declines in immune function, locomotor activity, learning and memory ([@CR42]; [@CR47]).

Caloric restriction treatment of Ames mice results in a further lifespan extension, indicating separate (though probably not fully independent) underlying mechanisms ([@CR8]). A mechanistic difference is also suggested by the observation that CR decelerates aging (the slope of the mortality curve decreases), whereas the mutation in Prop1 delays it (the mortality curve shifts to the right but maintains its shape) ([@CR8]). Moreover, effects of Ames dwarfism and CR on gene expression profiles and on expression of insulin-related genes are not the same ([@CR55]).

GHR-KO mice {#Sec6}
-----------

GHR-KO mice (Laron dwarf mice) lack a growth hormone receptor (GHR) because of a disrupted GHR/binding protein (GHR/BP) gene and are thus GH resistant ([@CR79]). These mice were generated to model the complete GH deficiency seen in human Laron syndrome. Laron syndrome, a recessively inherited disease with GH resistance, is characterized by very short stature, facial dysmorphism, truncal obesity, delayed puberty, recurrent hypoglycemia, low serum IGF-1 concentrations, elevated serum GH levels, absent, low, or dysfunctional serum GH-binding protein, and resistance to GH in patients ([@CR51]). As in human patients, growth is stunted in GHR-KO mice (adults are half the size of wild-type adults), and concentrations of circulating IGF-1 are very low to undetectable ([@CR79]). The lack of negative feedback of IGF-1 on GH secretion results in higher concentrations of circulating GH. Prolactin levels are also elevated. Plasma insulin and glucose concentrations are lower than normal in the GHR-KO mice, but insulin responsiveness is augmented, and reduced insulin release causes lowered glucose tolerance ([@CR25]; [@CR79]).

Comparing mouse phenotypes {#Sec7}
--------------------------

Interestingly, these two types of long-lived mutant mice exhibit delayed age-related cognitive decline while experiencing significant increase in both average and maximum life spans ([@CR46], [@CR47]; [@CR8]). There is an apparent contradiction between the evidence that those long-lived mutant mice with a circulating GH/IGF-1 deficiency have normal or improved cognitive function and the evidence that a decrease of GH and IGF-1 expression is related to cognitive malfunction. Interestingly, recent findings showed that both hippocampal GH and IGF-1 protein levels were increased and the corresponding mRNAs were normal in Ames dwarf as compared with normal mice ([@CR68], [@CR69]).

Given the previous evidence that circulating IGF-1 is undetectable in Ames dwarf mice, the IGF-1 immunoreactivity detected by Western blot in the hippocampus seems unlikely to be derived from peripheral circulation and transport across the blood-brain barrier. Thus, IGF-1 might be produced locally in the hippocampus and might also act directly on the neuronal progenitor cells in the DG ([@CR68]). Increased phosphorylation of Akt and cyclic AMP responsive element-binding protein (CREB) were detected in the hippocampus of aged Ames dwarf mice ([@CR68]). Evidence of activation of the anti-apoptosis signal transduction cascade was also found in the hippocampus of old dwarf mice (unpublished data). These data support the hypothesis that increase in hippocampal GH and IGF-1 protein expression and subsequent activation of PI3K/Akt-CREB and activation of anti-apoptosis signals might contribute to the maintenance of cognitive function and is likely to be responsible for the integrity of neuronal structure and maintenance of youthful levels of cognitive function in these long-lived mice during aging.

Evidence of increased hippocampal neurogenesis was found in the young adult Ames dwarf mice ([@CR69]). BrdU labeling studies showed an increase in numbers of newly generated cells (BrdU positive) and newborn neurons (neuronal nuclear antigen and BrdU positive) in the dentate gyrus of dwarfs compared with normal mice at 3 months of age ([@CR69]). Furthermore, there was a dramatic reduction of BrdU positive cells in the DG areas of both aged dwarf and normal mice, indicating an age-dependent decline of hippocampal neurogenesis.

In addition, there was no significant difference in the total number of BrdU-labeled cells between aged dwarf and normal mice (unpublished data). However, interestingly, the total number of newly generated neurons (BrdU and NeuN double positive) in old dwarf mice was significantly greater than in old normal mice (unpublished data). Considering the evidence for a significant increase in hippocampal IGF-1 protein expression and activation of an anti-apoptosis signal transduction cascade, it is likely that the increase in the fraction of newborn neurons in aged dwarf mice was due, at least in part, to an effect of local IGF-1 on cell survival.

Taking these data together, we speculate that aging influences the balance between neurogenesis and apoptosis in the mouse hippocampus as well as the process of the differentiation of the neuronal progenitors. Locally produced IGF-1 might work primarily as a promoting factor to increase neurogenesis in the DG area of the hippocampus in early adulthood; however, it functions mainly as a survival factor in the central nervous system to inhibit neuronal death during aging.
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